logo-loader
viewMylan Inc.

Mylan to launch two new low-cost HIV combination treatments in the US

Mylan said the treatments aim to address the high cost of other HIV therapies

health
Mylan plans to release the first of its two HIV therapies in coming weeks

Myan NV (NASDAQ:MYL) is to launch two new low-cost HIV combination treatments in the US after winning approval from the Food and Drug Administration.

Symfi Lo will be introduced in the coming weeks and Cimduo will be released in the second quarter.

The treatments aim to address the high cost of other HIV therapies, which account for more than US$20bn in annual spending, the company said.

Mylan is the world’s largest provider of HIV/AID treatments. It treats more than 40% of the 20 million patients across the globe.

In 2016 Mylan came under fire for raising the price of anti-allergy treatment, EpiPen, which saw chief executive Heather Bresch face tough questioning by a House Oversight Committee.

Quick facts: Mylan Inc.

Price: 16.36 USD

NASDAQ:MYL
Market: NASDAQ
Market Cap: $8.46 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Archer Materials hits another milestone with Quantum devices successfully...

Archer Materials (ASX: AXE) Chief Executive Officer DR Mohammad Choucair joined Steve Darling from Proactive to bring news the company has built Qubit control devices for quantum control measurements to characterise Archer’s unique 12CQ qubit processor chip components. Choucair talks about...

6 hours, 36 minutes ago

2 min read